Indivior Applauds Recent Momentum to Address Opioid Dependence and Overdose Epidemic

Slough, UK, 21 October 2015 – Indivior PLC (LON: INDV) is encouraged by recent efforts at the federal, state and local levels of government to expand access to treatment options as a means to help address the growing opioid dependence and overdose epidemic. The White House announcement of its plan to help reduce the rise in deaths from drug-related overdoses is another important step to confront this significant public health crisis. Efforts include providing greater access to treatment for opioid dependence, training to properly prescribe opioid medications and increasing availability of naloxone.

This announcement aligns with initiatives, such as the United States Department of Health and Human Services (HHS) Secretary Sylvia M. Burwell’s plan to revise rules around access to medication-assisted treatment (MAT). According to the Substance Abuse and Mental Health Services Administration (SAMHSA), there were 2.5 million people (aged 12 or older) who abused or were dependent on painkillers or heroin in 2014.1

“Indivior supports the increased emphasis and growing momentum in recent weeks to help expand patient access to treatment,” said Indivior Chief Executive Officer Shaun Thaxter. “These policy initiatives proposed by the federal government are a major step forward in addressing the growing epidemic of opioid dependence and overdose in this country. Increasing access to medication-assisted treatment, (MAT), including buprenorphine, as well as empowering communities to put naloxone directly into the hands of the layperson, trained healthcare personnel or first responders to administer treatment at the scene of an overdose, is an important step, as every second counts. Indivior is committed to working together with stakeholders to fundamentally impact this public health crisis and help improve patient outcomes.”


About Indivior
Indivior is a global specialty pharmaceutical company with a 20-year legacy in patient advocacy, health policy and evidence-based best practice models that have helped to advance modern addiction treatment. The name is the fusion of the words individual and endeavor, and the tagline “Focus on you” makes the company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global opioid dependence portfolio, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and address other chronic diseases of addiction – including opiate overdose, alcohol use disorders and cocaine intoxication. It also is pursuing novel product candidates in related mental health disorders such as schizophrenia. Headquartered in the United States in Richmond, Va., Indivior employs more than 700 individuals globally and its portfolio is available in over 40 countries worldwide. Visit to learn more.


Forward-Looking Statements

This press release contains forward-looking statements. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations.

Various factors may cause differences between Indivior’s expectations and actual results, including: factors affecting sales of Indivior products and any future products; the outcome of research and development activities; decisions by regulatory authorities regarding the Indivior Group’s drug applications; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the outcome of post-approval clinical trials; competitive developments; difficulties or delays in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy of the Indivior Group’s products and product candidates; risks related to legal proceedings; the Indivior Group’s ability to protect its patents and other intellectual property; the outcome of patent litigation relating to ongoing ANDA lawsuits; changes in governmental laws and regulations; issues related to the outsourcing of certain operational and staff functions to third parties; uncertainties related to general economic, political, business, industry, regulatory and market conditions; and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product recalls and withdrawals and other unusual items.

Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.


Media Contacts
Jonathan Steed
Biosector 2
+1 212-845-8421


Beth Keshishian
Biosector 2
+1 212-229-8417


Investor Contact
Tom Corran
Indivior, Director, Investor Relations
+44(0)175 321 780




1 Substance Abuse and Mental Health Services Administration. SAMHSA Behavioral Health Trends in the United States: Results from the 2014 National survey on Drug Use and Health. HHS Publication No. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014.